Printed From:

Lantus® is a Basal Insulin That Provides Once-Daily Dosing2

A longer action profile than detemir demonstrates true once-daily dosing.1

Study Design

Twenty-four subjects with type 1 diabetes naïve to glargine and detemir were studied twice in a randomized, double-blind crossover study. Plasma glucose was clamped at 100 mg/dL for 24 hours after subcutaneous injection of 0.35 Units/kg of either Lantus® or detemir.

From Porcellati.1
aGlucose infusion rate (mg/kg/min).
  • Detemir has effects similar to those of Lantus® during the initial 12 hours after administration, but effects are lower during 12-24 hours
  • Duration of action (time at which PG >118 mg/dL) for a single dose of detemir is shorter than for Lantus® (15.5 vs 24 hours)

Important Considerations

  • Detemir is approved to be administered once or twice daily
  • The time course of action of insulins, including Lantus®, may vary between individuals and within the same individual
Lantus® has no pronounced peak, so it mimics the steady rate of physiologic basal insulin secretion.2

Action Profiles of Detemir and NPH in Patients With Type 1 Diabetes

Study Design

In a single-center, double-blind, 6-period, randomized, dose-response trial, 12 isoglycemic (130 mg/dL), C-peptide-negative (<0.03 nmol/L) subjects with type 1 diabetes were randomized to a specific treatment sequence encompassing 5 dose levels of insulin detemir (0.1, 0.2, 0.4, 0.8, and 1.6 Units/kg) and 1 dose level of NPH insulin (0.3 Units/kg).

From Plank3 and Levemir Prescribing Information.4
aGlucose infusion rate (mg/kg/min).

  • Detemir is approved to be administered once or twice daily4
  • The mean duration of action of detemir ranged from 5.7 hours at the lowest dose to 23.2 hours at the highest dose (sampling period of 24 hours)4
  • The time course of action of insulins may vary between individuals and within the same individual

References:

  1. Porcellati F, Rossetti P, Busciantella NR, et al. Diabetes Care. 2007;30(10):2447-2452.
  2. Lantus® Prescribing Information. February 2015.
  3. Plank J, Bodenlenz M, Sinner F, et al. Diabetes Care. 2005;28(5): 1107-1112.
  4. Levemir Prescribing Information. February 2015.

Proven HbA1c control

See how Lantus® provides effective, improved glycemic control in diabetes patients.

Lantus® Prescribing Information. February 2015.

Once-daily dosing

Lantus® is a once-daily, long-acting insulin.**

**Lantus® Prescribing Information. February 2015.

Demonstrated long-term CV safety

Lantus® is a basal insulin with demonstrated long-term CV safety data††

††Including CV death, nonfatal MI, nonfatal stroke, revascularization, or hospitalization for heart failure. No difference was observed between Lantus® and standard of care in overall incidence of CV death, nonfatal MI, or nonfatal stroke. No difference was observed between treatment groups for death of any cause.